| Literature DB >> 32460429 |
Jay M Mirtallo1,2, Phil Ayers3, Joseph Boullata4, Kathleen M Gura5,6, Steven Plogsted7, Collin R Anderson8, Patricia Worthington7, David S Seres9, Emily Nicolai10, Mohammad Alsharhan11, Liliia Gutsul12, Angelina E Mason13.
Abstract
Lipid injectable emulsions (ILEs) are complex pharmaceutical formulations used as a source of energy and essential fatty acids in parenteral nutrition. Issues associated with ILE use are distinctly different from oral fat and arise from emulsion stability, dose, and infusion tolerance. Since 1975, soybean oil has been the consistent source oil used in ILE formulations in the US. Partly because of safety concerns with the soybean-based ILE and frequent and long-standing problems with product inventory shortages, new ILE products have become available. Gaps in ILE best practices create a risk for ILE safety errors in prescribing, compounding, and administration of these products. This paper provides information on appropriate indications, dosing, and methods to avoid potential errors with ILE products in the US. This paper (Part 1) will focus on ILE background, information, and recommendations for adult patients, whereas Part 2 of this series will focus on neonatal and pediatric patient-specific information.Entities:
Keywords: lipid injectable emulsion; parenteral nutrition process; recommendations; safety
Mesh:
Substances:
Year: 2020 PMID: 32460429 DOI: 10.1002/ncp.10496
Source DB: PubMed Journal: Nutr Clin Pract ISSN: 0884-5336 Impact factor: 3.080